Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines (2023)
Sequence: Ac-K(cholesterol)-βA-βA-WWWW-βA-βA-RRRR-CONH2
| Experiment Id | EXP000838 |
|---|---|
| Paper | Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines |
| Peptide | MLP5 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | ≤8.64 µM (max at N/P 40, reported) |
| Rna Concentration | 36 nM (reported for uptake assay; likely similar in functional assays) |
| Mixing Ratio | N/P 20, 40 |
| Formulation Format | peptide/siRNA electrostatic complex (N/P ratio) |
| Formulation Components | MLP peptide + siRNA (saline) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDA-MB-231 |
| Animal Model | |
| Administration Route | |
| Output Type | STAT3 protein downregulation (Western blot) |
| Output Value | >90% STAT3 downregulation at N/P 40; reduced efficacy at N/P 20 |
| Output Units | |
| Output Notes | Cholesterol-conjugated; >50% siRNA uptake by FACS; confocal imaging shows cytosolic siRNA signal comparable to Lipofectamine. |
| Toxicity Notes | No significant cytotoxicity up to 10 µM; in peptide/siRNA complexes, max peptide concentration at N/P 40 was 8.64 µM (MTS, 48 h). |
| Curation Notes |